Celgene

To see an up-to date selection of historical analyses and insights on Celgene, visit our new, dynamically updated Company Summary report pages for Celgene.

As a Guest User, you will have FREE access to a selection of historical analyses and insights from EvaluatePharma®.

How to access FREE content

  • Search the content using the search box at the top of every page
  • Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
  • Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar

Register for FREE to access even more content including 2007 Product Sales and Rankings.

A small selected sample of reports and related news headlines for Celgene are available below. Free sample reports are also available for other Companies.

To find out how you can access more detailed information on Celgene, or on any other Company covered by EvaluatePharma® Contact Us today.

NEWS - Selected Product News Headlines (as of 11 June 2008)
Therapeutic focus - Behind Tracleer pulmonary fibrosis pipeline is a trickle   (InterMune)   (Invalid Date)
Intergroupe Francophone du Myelome (IFM) Phase III Study (IFM 2005 02) Evaluating Treatment with Continuous REVLIMID(R) in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant Meets Primary Endpoint   (Celgene)   (Invalid Date)
Initial Data from CALGB-Led Study of Treatment with Continuous REVLIMID(R) in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant Reported   (Celgene)   (Invalid Date)
Positive Phase IIb Topline Clinical Data for Celgene Oral Compound Apremilast (CC-10004) Reported for Patients with Moderate-to-Severe Psoriasis   (Celgene)   (Invalid Date)
Ash 2009 EventAnalyzer – winners and losers   (Sunesis Pharmaceuticals)   (Invalid Date)
Celgene's Revlimid data prompts questions but high hopes remain   (Celgene)   (Invalid Date)
Nippon Shinyaku Co., Ltd. Submits New Drug Application for a Therapeutic Agent for Myelodysplastic Syndromes (MDS) in Japan.   (Nippon Shinyaku)   (Invalid Date)
First Randomised Study Comparing All-Oral REVLIMID(R) Regimen Compared to Autologous Stem Cell Transplant Presented at ASH   (Celgene)   (Invalid Date)
Phase II Data Evaluating REVLIMID(R) + Rituximab in Relapsed Patients with Chronic Lymphocytic Leukaemia Presented at American Society of Hematology   (Celgene)   (Invalid Date)
Two Studies Evaluating the Clinical Potential of Pomalidomide for the Treatment of Multiple Myeloma Patients Refractory to Novel Therapies Presented at the American Society of Hematology Meeting   (Celgene)   (Invalid Date)
Multi-Centre, Randomised, Controlled Study Results Evaluating the Clinical Potential of REVLIMID(R) in Patients with Smoldering Multiple Myeloma Presented at ASH   (Celgene)   (Invalid Date)
First Interim Analysis After Less Than 10-Months of Phase III Study Shows That Continuous REVLIMID(R) Therapy is Superior to Fixed Duration Regimens in Newly Diagnosed Elderly Multiple Myeloma Patients   (Celgene)   (Invalid Date)
Updated Data from Randomized Controlled Phase II Study Evaluating Oral Apremilast in Psoriatic Arthritis Demonstrates Sustained Response at Six Months   (Celgene)   (Invalid Date)
Clinical Data Evaluating Amrubicin(R) as Potential Therapy for Patients with Small Cell Lung Cancer Presented at 13th World Conference on Lung Cancer   (Celgene)   (Invalid Date)
Acceleron and Celgene Initiate Phase 2 Study of ACE-011 to Treat Chemotherapy-Induced Anemia   (Acceleron Pharma)   (Invalid Date)
Celgene Announces New Drug Application Filing for REVLIMID(R) in Japan   (Celgene)   (Invalid Date)
Celgene Announces Positive Top Line Data from Randomized Controlled Phase II Study of Apremilast in Psoriatic Arthritis   (Celgene)   (Invalid Date)
Innovative Therapy Improving Responses, Survival in Multiple Myeloma Patients According to Presentations at the 14th Congress of the European Hematology Association   (Celgene)   (Invalid Date)
Presentations at the 14th Congress of the European Hematology Association Demonstrate VIDAZA(R) Benefits Patients with Myelodysplastic Syndromes   (Celgene)   (Invalid Date)
Data From REVLIMID(R) VIDAZA(R) and Amrubicin Clinical Trials Reported in Expanded Haematology and Oncology Indications   (Celgene)   (Invalid Date)
Landmark Study Published in The Lancet Oncology Shows Celgene's Vidaza(R) Demonstrates Unprecedented Overall Survival in Intermediate-2 and High-Risk Myelodysplastic Syndromes, as Well as Acute Myeloid Leukaemia   (Celgene)   (Invalid Date)

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts.

Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®.

Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.

Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.